Debt-to-equity of GT Biopharma, Inc. from 30 Sep 2014 to 31 Mar 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
GT Biopharma, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2014 to 31 Mar 2024.
  • GT Biopharma, Inc. Debt-to-equity for the quarter ending 31 Mar 2024 was 69%, a 49% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

GT Biopharma, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q1 2024 69% +23% +49% 31 Mar 2024
Q4 2023 62% +15% +32% 31 Dec 2023
Q3 2023 53% +5% +11% 30 Sep 2023
Q2 2023 45% 30 Jun 2023
Q1 2023 46% 31 Mar 2023
Q4 2022 47% 31 Dec 2022
Q3 2022 47% 30 Sep 2022
Q1 2020 -154% -173% -938% 31 Mar 2020
Q4 2019 -380% -388% -4917% 31 Dec 2019
Q3 2019 539% +535% +13638% 30 Sep 2019
Q2 2019 136% +134% +6910% 30 Jun 2019
Q1 2019 18% 31 Mar 2019
Q4 2018 8% 31 Dec 2018
Q3 2018 4% 30 Sep 2018
Q2 2018 2% 30 Jun 2018
Q1 2017 -101% -1% -0.89% 31 Mar 2017
Q4 2016 -101% 0% +0.31% 31 Dec 2016
Q3 2016 -101% +1% +1.3% 30 Sep 2016
Q2 2016 -100% +2% +2.3% 30 Jun 2016
Q1 2016 -100% +3% +2.8% 31 Mar 2016
Q4 2015 -101% +2% +2.1% 31 Dec 2015
Q3 2015 -102% +1% +1.3% 30 Sep 2015
Q2 2015 -103% 30 Jun 2015
Q1 2015 -103% 31 Mar 2015
Q4 2014 -103% 31 Dec 2014
Q3 2014 -103% 30 Sep 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.